中国创新药“Deepseek时刻”,数不过来了?

MedTrend医趋势
Jul 03, 2025

短短48小时,中国创新药行业接连放出两个“重磅炸弹”——一边是百利天恒,其全球首个EGFR×HER3双抗ADC,在鼻咽癌III期临床试验中达成主要终点。全新概念、全球首创、自主研发,这款产品几乎占全了“创新药的性感标签”。另一边是迪哲医药,其核心产品舒沃哲正式获得FDA批准,适应症为EGFR exon20ins突变的晚期非小细胞肺癌,这是中国首个独立研发在美获批的全球首创新药。一前一后,两家公司...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10